{"filings":[{"id":443477,"accession_number":"0001193125-26-224161","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2026-05-14T20:29:55+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Zymeworks authorizes $125M share repurchase program, expects cash runway beyond 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $125M share repurchase of common stock under 2026 program.","Prior 2025 program terminated; 4,197,553 shares repurchased at avg $24.36 for $102.3M.","Company expects existing cash plus $440M milestone payments for Ziihera to fund operations beyond 2028.","Approximately 73.0M shares outstanding as of May 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96811,"accession_number":"0001937653-26-000033","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zymeworks Q1 net loss $44.2M; Jazz's zanidatamab sBLA accepted with Priority Review, PDUFA Aug 25, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Jazz sBLA for zanidatamab in 1L HER2+ GEA accepted with Priority Review; PDUFA target date Aug 25, 2026.","Upon US FDA approval, Zymeworks eligible for $250M milestone from Jazz; $15M from BeOne for China approval.","Q1 2026 revenue $2.4M (down 91% YoY from $27.1M); net loss $44.2M vs $22.6M loss in Q1 2025.","Cash and marketable securities $403.8M as of Mar 31, 2026; $95.8M used for share repurchases under $125M program.","ZW191 Phase 1 data at AACR: 56% ORR in PROC, 61% in ovarian, 57% in endometrial; FDA Fast Track granted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":2408000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96810,"accession_number":"0001193125-26-135610","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zymeworks appoints Kristin Stafford as CFO, effective April 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stafford previously SVP, CAO at Royalty Pharma; brings life sciences capital markets experience.","Compensation includes $520K annual base salary, 45% target bonus, $52K signing bonus.","Equity awards: 178K options, 119K RSUs (4-year vest), and 50K RSUs (3-year vest).","Kenneth Galbraith ceases as interim CFO but remains CEO and Chairman of the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111063,"accession_number":"0001937653-26-000013","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zymeworks FY2025 revenue up 39% to $106M, net loss down 34%; $250M royalty-backed note from Royalty Pharma","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $106.0M (+39% YoY); net loss $81.1M vs $122.7M in 2024.","Cash & securities $270.6M as of Dec 31; $62.5M used for share repurchases at avg $24.22/share.","Entered $250M non-recourse royalty-backed note with Royalty Pharma; 70% of Ziihera royalty unencumbered.","Partner Jazz expects Ziihera sBLA submission in 1Q 2026, potential launch in 2H 2026; up to $440M milestones eligible.","2026 adjusted gross opex guided ~20% lower than 2025 adjusted opex of $170.5M, excluding acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111062,"accession_number":"0001193125-26-084082","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Zymeworks secures $250M non-recourse royalty-backed note from Royalty Pharma on Ziihera royalties","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repayment from 30% of Ziihera tiered royalties; total due $412.5M if paid by Dec 2033 or $481.3M by Dec 2042.","Zymeworks retains 70% of Ziihera royalties during repayment; full royalty rights revert after Royalty Pharma payments cease.","Proceeds strengthen balance sheet non-dilutively, support share repurchases, strategic acquisitions, and cash runway beyond 2028.","All regulatory and commercial milestones from Jazz and BeOne agreements (up to $1.5B potential) retained by Zymeworks.","Transaction involves Royalty Pharma (RPRX) as lender; Covington, Gibson Dunn, Choate, Maiwald as legal advisors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111061,"accession_number":"0001193125-26-010480","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"Zymeworks terminates CFO, reports ~$270.6M cash; new COO and CMO appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Leone Patterson terminated without cause Jan 9; CEO Kenneth Galbraith appointed interim CFO.","Preliminary cash $270.6M as of Dec 31, 2025; expects $440M milestones from Ziihera approvals in US/EU/Japan/China.","$125M share repurchase plan announced Nov 2025; cash runway guided beyond 2028.","Mark Hollywood promoted to COO (base salary $525K); Brian Cherry appointed Class II director.","CMO Jeffrey Smith retiring Jan 31; Sabeen Mekan appointed CMO effective Feb 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127686,"accession_number":"0001193125-25-337268","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zymeworks annual meeting elects three directors, approves say-on-pay, ratifies KPMG","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected directors Campoy (94.4%), Cesano (80.5%), Landry (96.9%); broker non-votes 6.07M.","Advisory say-on-pay approved: 93.98% for, 5.93% against, 0.09% abstain; 6.07M broker non-votes.","Ratified KPMG as auditor: 99.54% for, 0.42% against, 0.04% abstain; no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127685,"accession_number":"0001193125-25-285259","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["5.02","8.01","7.01","9.01"],"status":"ready","headline":"Zymeworks shifts to royalty-driven model, authorizes $125M buyback; appoints Platshon as CIO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eligible for up to $440M in near-term milestones from Ziihera GEA approvals ($250M US, $100M EU, $75M Japan, $15M China).","Board authorized $125M share repurchase program; prior $60M buyback retired ~4.4M shares (6% of outstanding).","Cash and investments $299.4M as of Sep 30, 2025; with milestones expects to fund operations beyond 2028.","Scott Platshon stepped down from board, appointed Acting CIO to manage healthcare asset aggregation strategy.","Also eligible for up to $434M in additional milestones from J&J for pasritamig Phase 3 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127684,"accession_number":"0001193125-25-283873","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zymeworks announces positive Phase 3 results for Ziihera in first-line HER2+ GEA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ziihera + chemo showed statistically significant PFS improvement vs trastuzumab + chemo; OS trend with further analysis expected mid-2026.","Ziihera + Tevimbra (tislelizumab) + chemo showed statistically significant improvements in both OS and PFS vs control.","PFS and OS benefit observed across PD-L1 positive and negative subgroups in the triple combo arm.","Jazz plans to submit supplemental BLA in 1H-2026; Zymeworks eligible for milestones and royalties.","Safety profile consistent with known safety of each agent; no new signals observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127683,"accession_number":"0001937653-25-000076","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zymeworks Q3 2025 revenue $27.6M, net loss narrows to $19.6M; positive ZW191 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $27.6M (up from $16.0M YoY) driven by $25.0M J&J milestone; net loss $19.6M vs $29.9M.","Cash resources $299.4M as of Sep 30, 2025; projected runway into 2H-2027 including anticipated milestones.","Encouraging Phase 1 data for ZW191 (FRα ADC): 53% objective response rate (64% in gynecological cancers).","First patient dosed in Phase 1 trial of ZW251 (GPC3-targeting ADC) for hepatocellular carcinoma.","Completed $22.7M in share repurchases (1.44M shares at avg $15.80) under remaining $30.0M program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":103450000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144462,"accession_number":"0001193125-25-193351","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zymeworks discontinues ZW171 Phase 1 after dose escalation; benefit-risk profile unfavorable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Decision based on completed dose escalation in ovarian and NSCLC patients; MTD established but benefit-risk not supportive.","Dose-limiting toxicities consistent with mesothelin-related on-target off-tumor toxicity; CRS was well-managed.","Ongoing participants may continue at investigator discretion; discontinued patients remain in safety follow-up.","Pipeline continues: ZW191 Phase 1 ongoing, ZW251 Phase 1 expected 2025, ZW209 IND filing planned H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144461,"accession_number":"0001193125-25-177505","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["1.01","5.02","3.02","8.01","9.01"],"status":"ready","headline":"Zymeworks appoints Ciongoli and Landry to board; Cox resigns; private placement of $4.99M to Ciongoli","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gregory Ciongoli and Robert E. Landry appointed as directors effective Aug 10, 2025; Ciongoli as Class II, Landry as Class I; both join Audit Committee.","Troy M. Cox resigned from Board and Audit Committee effective Aug 9, 2025; no disagreement with company.","Company sold 415,000 shares to Ciongoli at $12.02/share for aggregate $4,988,300 in unregistered private placement.","Proceeds from private placement will be used for working capital and general corporate purposes; closing expected Aug 12, 2025.","Press release highlights upcoming Q4 2025 data readout for HERIZON-GEA-01 and recent zanidatamab approvals in US, Europe, and China."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144460,"accession_number":"0001937653-25-000047","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zymeworks posts Q2 net income of $2.3M on revenue of $48.7M; cash runway into 2H-2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $48.7M in Q2 2025 vs $19.2M in Q2 2024, driven by $20M BeOne milestone and $7.5M BMS license option.","Net income of $2.3M compared to net loss of $37.7M in Q2 2024; R&D expenses $34.4M, G&A $15.0M.","Cash resources $333.4M as of June 30, 2025, projected to fund operations into 2H-2027 with anticipated milestones.","FDA cleared IND for ZW251 (GPC3-targeting ADC); Phase 1 planned for 2025, joining ZW171 and ZW191 in clinic.","Jazz reported Ziihera net sales of $5.5M in Q2; conditional EU approval for HER2+ BTC and China approval noted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":75836000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162829,"accession_number":"0001193125-25-151279","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Zymeworks removes warrant cap; EcoR1 exercises for 5.1M shares, diluting by ~7%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Removed 19.99% beneficial ownership cap on pre-funded warrants held by EcoR1 Capital.","EcoR1 net exercised warrants for 5,086,480 shares of common stock at $0.0001 per share on June 26, 2025.","Outstanding shares increased to 74,844,505 from ~69.8M, representing ~7% dilution.","Warrants originally issued Dec 2023 at $9.83 each for $50M; exercise provides no new cash.","Oleg Nodelman and Scott Platshon, both board members, represent EcoR1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162828,"accession_number":"0001193125-25-132299","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zymeworks' zanidatamab wins NMPA conditional approval in China for HER2+ BTC; $20M milestone due","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NMPA (China) conditionally approved zanidatamab for previously treated unresectable/metastatic HER2+ biliary tract cancer (IHC3+).","Zymeworks receives $20M milestone from BeOne Medicines (formerly BeiGene); already received $61M in prior payments.","Eligible for up to $144M in additional development/commercial milestones and tiered royalties up to 19.5% on net sales.","Approval based on HERIZON-BTC-01 study showing overall survival benefit; confirmatory trials ongoing.","Zanidatamab previously approved by FDA (Nov 2024); EMA CHMP positive opinion (Apr 2025) for same indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162827,"accession_number":"0001937653-25-000026","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zymeworks Q1 revenue $27.1M, net loss narrows to $22.6M; cash runway into 2H-2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $27.1M (vs. $10.0M in Q1 2024); net loss of $22.6M improved from $31.7M.","Cash resources $321.6M; combined with anticipated milestones expected to fund operations into 2H-2027.","Partner Jazz received EMA positive opinion for zanidatamab in HER2+ BTC; final decision pending.","Recognized $14.0M GSK milestone (paid Apr 2025) and $3.1M Daiichi Sankyo milestone; additional milestones remain.","Appointed Dr. Sabeen Mekan as SVP Clinical Development; six preclinical posters presented at AACR."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":27110000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180786,"accession_number":"0001937653-25-000012","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zymeworks reports $122.7M net loss for 2024; Ziihera approval drives $25M milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $76.3M in 2024 (vs $76.0M in 2023); net loss $122.7M vs $118.7M loss prior year.","Cash resources $324.2M at Dec 31, 2024; projected runway into 2H-2027 with anticipated regulatory milestones.","Ziihera (zanidatamab) FDA approved for HER2+ BTC in Nov 2024; initial net sales $1.1M; $25M milestone earned from Jazz.","Phase 1 studies initiated for ZW191 and ZW171; IND for ZW251 accelerated to mid-2025; ZW220 preparations paused.","Non-cash impairment charge of $17.3M for discontinuation of zanidatamab zovodotin; $14M milestone from GSK in Jan 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180785,"accession_number":"0001193125-25-028050","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Zymeworks appoints Oleg Nodelman (EcoR1 Capital founder) to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nodelman appointed Class II director effective Feb 17, 2025; term expires at 2026 AGM.","Nodelman waived director compensation; named to Nominating Committee.","Scott Platshon (EcoR1 partner) appointed to Compensation Committee, effective same date.","EcoR1 is Zymeworks' largest stockholder; Nodelman joins under board renewal, not prior nomination right.","Board added 7 new directors over two years as part of renewal process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180784,"accession_number":"0001193125-25-003519","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Zymeworks reports $324M cash, provides 2025-2026 pipeline milestones and cash runway into 2H-2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash resources ~$324M as of Dec 31, 2024, plus $25M milestone from Jazz expected in Q1 2025.","Cash runway expected to fund planned operations into 2H-2027, including anticipated regulatory milestone payments.","Phase 3 HERIZON-GEA-01 top-line results for zanidatamab in first-line GEA expected 2Q 2025; sBLA later in 2025.","Potential EU approval for zanidatamab in second-line BTC as early as 2Q 2025; China NMPA decision as early as 2H 2025.","IND applications for ZW220, ZW251 in solid tumors in 2025; ZW209 and ZW1528 (AIID) INDs in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197635,"accession_number":"0001193125-24-275534","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Zymeworks reports annual meeting results and amends director compensation policy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected four directors with 82-99% votes for; KPMG ratified as auditor with 96.86% votes for.","Advisory vote on named executive officer compensation approved with 93.33% votes for.","Board increased R&D committee retainer from $6,000 to $7,500 effective Jan 1, 2025.","Initial option grant for new directors reduced from 74k to 62k shares; annual grant from 37k to 31k."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197634,"accession_number":"0001193125-24-263398","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA grants accelerated approval to Zymeworks' Ziihera for HER2+ BTC; $25M milestone earned","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Ziihera (zanidatamab-hrii) approved for adults with previously-treated unresectable/metastatic HER2+ BTC.","Approval based on 52% objective response rate and median DOR of 14.9 months from HERIZON-BTC-01 trial.","Zymeworks earns $25M milestone from Jazz; eligible for up to $500M regulatory + $862.5M commercial milestones.","Continued approval contingent on Phase 3 HERIZON-BTC-302 confirmatory trial.","Zanidatamab also in Phase 3 trials for GEA (top-line PFS data Q2 2025) and mBC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197633,"accession_number":"0001937653-24-000049","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zymeworks reports 9M 2024 net loss $99.2M; cash $374.9M; completes $30M buyback; advances pipeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $99.2M for nine months ended Sep 30, 2024 vs $104.2M loss prior year; revenue $45.3M vs $59.1M.","Cash resources $374.9M (cash, equivalents, marketable securities) as of Sep 30, 2024; projected runway into 2H 2027 including milestones.","Completed initial $30M share repurchase: 2,545,402 shares at avg $11.79 as of Oct 31, 2024.","First patient dosed in Phase 1 trial of ZW171 for MSLN-expressing cancers; preclinical data presented for ZW220 and ZW251.","Director Hollings C. Renton resigns from board effective Dec 10, 2024; not due to disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":45273000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197632,"accession_number":"0001193125-24-239630","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Zymeworks board member Renton to resign Dec 10, 2024; Gallagher and Mahony appointed to compensation committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hollings C. Renton resigns from board and as compensation committee chair, effective Dec 10, 2024 (annual meeting date).","Resignation not due to any disagreement with the company on operations, policies or practices.","Dr. Neil Gallagher appointed to compensation committee; Dr. Susan Mahony named committee chair.","Committee composition updated: Mahony (Compensation chair), Gallagher (member), others unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213867,"accession_number":"0001193125-24-212062","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Leone Patterson starts as CFO on Sept 1; Galbraith resigns as interim CFO but remains CEO/Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leone Patterson, age 61, commenced as EVP, Chief Business Officer and CFO on September 1, 2024.","Kenneth Galbraith resigned as interim CFO and principal financial/accounting officer, effective Sept 1, 2024.","Galbraith continues as Chair, CEO and President of Zymeworks; his compensation unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213866,"accession_number":"0001193125-24-192058","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Zymeworks enters ATM sales agreement with TD Cowen for at-the-market stock offerings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement dated August 2, 2024 with TD Securities (USA) LLC (TD Cowen) as sales agent.","Shares offered via methods permitted under Rule 415(a)(4), including on Nasdaq.","Commission of up to 3.0% of gross proceeds on any shares sold under the agreement.","Company is not obligated to sell any shares and may terminate agreement at any time.","Offered under existing S-3ASR registration statement filed May 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213865,"accession_number":"0001937653-24-000039","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zymeworks Q2 2024 net loss $69.3M; cash $395.9M; zanidatamab BLA priority review by Nov 29","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for H1 2024: $69.3M vs $75.5M loss in H1 2023; revenue $29.3M (down from $42.6M).","Cash, equivalents and marketable securities $395.9M as of June 30, 2024; runway into 2H 2027.","FDA granted Priority Review for zanidatamab BLA in 2L HER2+ BTC; PDUFA date Nov 29, 2024.","Discontinued zanidatamab zovodotin (ZW49) to focus on ZW171 and ZW191 Phase 1 starts in 2H 2024.","Appointed Leone Patterson as EVP, Chief Business Officer and CFO, effective Sep 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":29273000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213864,"accession_number":"0001193125-24-191535","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Zymeworks authorizes $60M share repurchase; initial $30M in H2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $60M of common stock; initial $30M anticipated to begin promptly in second half of 2024.","Remaining $30M reserved for future repurchases to maintain flexibility for market conditions and growth.","Company expects existing cash plus regulatory milestone payments to fund planned operations into second half of 2027 despite repurchases.","CEO Kenneth Galbraith cites confidence in pipeline and commitment to returning capital to shareholders, noting stock undervalued.","Repurchases may be made in open market under Rule 10b5-1 and Rule 10b-18; program may be suspended or discontinued anytime."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213863,"accession_number":"0001193125-24-184871","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zymeworks appoints Leone Patterson as EVP, Chief Business & CFO effective Sept 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ms. Patterson appointed EVP, Chief Business Officer and CFO; start date Sept 1, 2024.","Kenneth Galbraith to step down as interim CFO but remain Chair and CEO.","Compensation: $485K base salary, 45% bonus target, $50K signing bonus, 360,000 inducement stock options.","Amended Inducement Plan increases share reserve by 700,000 shares to 1,450,000 total since plan inception.","Ms. Patterson brings over 20 years biotech CFO/CEO experience from Tenaya, Adverum, etc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233086,"accession_number":"0001193125-24-158341","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NMPA accepts zanidatamab BLA in China; Zymeworks earns $8M milestone from BeiGene","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["China's NMPA accepted BLA for zanidatamab in second-line HER2+ biliary tract cancer.","Acceptance triggers $8 million milestone payment from partner BeiGene under Asia Pacific license.","FDA previously granted priority review for same indication; PDUFA target date Nov 29, 2024.","Zanidatamab is also being developed by Jazz Pharmaceuticals in the U.S.","Milestone payment expected to be received following NMPA acceptance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233085,"accession_number":"0001193125-24-130781","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zymeworks files prospectus supplement for up to $150M at-the-market offering via Cantor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registers up to $150M in common stock for sale through Cantor Fitzgerald as sales agent (ATM offering).","Also registers 570,637 shares of common stock issuable upon exchange of exchangeable shares from prior redomicile.","Prospectus supplements dated May 3, 2024, to existing Form S-3ASR shelf registration statement.","Legal opinions from Wilson Sonsini Goodrich & Rosati filed as exhibits 5.1 and 5.2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233084,"accession_number":"0001937653-24-000027","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zymeworks Q1 net loss $31.7M, revenue $10M; cash $420.5M, runway into 2H27","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell to $10.0M from $35.6M YoY due to transfer of zanidatamab responsibilities to Jazz.","Net loss widened to $31.7M vs $24.4M in Q1 2023; R&D expense decreased 30% to $32.0M.","Cash resources $420.5M; combined with anticipated milestones, funded into 2H 2027.","Partner Jazz completed rolling BLA submission to FDA for zanidatamab in BTC; Phase 3 breast cancer trial planned H2 2024.","On track for two IND submissions in 2024 for ZW191 and ZW171; Dr. Neil Gallagher joined board."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":10030000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233083,"accession_number":"0001193125-24-086214","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zymeworks removes CFO Christopher Astle effective March 31; severance $425,000","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Astle removed as CFO and principal accounting officer without cause, effective March 31, 2024.","Severance package includes $425,000 lump sum (12 months' base salary) and 12 months of health benefits.","Astle retains 92,369 vested stock options (90 days to exercise); 146,881 unvested options and 51,000 unvested RSUs forfeited.","CEO Kenneth Galbraith serves as interim CFO; no permanent replacement announced.","Separation agreement includes non-solicitation, non-competition, and confidentiality covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233082,"accession_number":"0001193125-24-082784","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zymeworks removes CFO Christopher Astle; CEO Kenneth Galbraith named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Christopher Astle removed as SVP and CFO, including principal financial and accounting officer, effective March 31, 2024.","Kenneth Galbraith, Chair, President, and CEO, appointed interim CFO, assuming principal financial and accounting duties.","Company has initiated a search for a new permanent CFO.","Mr. Galbraith's compensation arrangements remain unchanged per prior filings.","No family relationships or arrangements with other persons regarding the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251242,"accession_number":"0001193125-24-080641","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Zymeworks appoints Dr. Neil Gallagher to board; 6th new director in 12 months","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gallagher joins board effective April 2, 2024 as Class I director, term to 2025 AGM.","He will receive initial option grant for 74,000 common shares on appointment.","Gallagher appointed to R&D committee; full committee composition updated (see filing).","Gallagher is President & Head of R&D at Syndax Pharmaceuticals; ex-AbbVie, Amgen, Novartis.","CEO says appointment supports advancement of '5 by 5' clinical programs and pipeline expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251241,"accession_number":"0001937653-24-000017","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zymeworks reports FY 2023 net loss of $118.7M; zanidatamab BLA initiated; cash runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $76.0M vs $412.5M in 2022, reflecting non-recurring Jazz upfront; net loss of $118.7M vs net income $124.3M.","Cash, cash equivalents and marketable securities $456.3M as of Dec 31; with milestone payments, runway into 2H 2027.","Rolling BLA for zanidatamab in second-line biliary tract cancers started by Jazz; expected completion 1H 2024.","Jazz initiated Phase 3 confirmatory trial for zanidatamab as first-line BTC; BeiGene expects NMPA BLA filing 2H 2024.","Targeting two IND submissions in 2024 (ZW191, ZW171); ZW49 Phase 2 deprioritized pending collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251240,"accession_number":"0001193125-24-042846","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Scott Platshon appointed to Zymeworks board; EcoR1 Capital partner joins","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed as Class III director effective Feb. 22, 2024; term expires at 2024 annual meeting.","Appointment follows EcoR1's $50M investment in Dec 2023 (5.09M pre-funded warrants at $9.83/share).","Platshon waived cash and equity compensation under director compensation policy.","EcoR1's board nomination right terminates upon appointment or Jan. 1, 2026, whichever earliest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251239,"accession_number":"0001193125-24-028369","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Zymeworks appoints Dr. Cesano to board; Dr. Hillan resigns after 7 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Alessandra Cesano appointed to board effective Feb 8, 2024, as Class I director with term expiring at 2025 AGM.","Dr. Kenneth Hillan resigned Feb 6, effective Feb 8, not due to disagreement; he served 7 years on the board.","Cesano receives initial option to purchase 74,000 shares per standard non-employee director compensation plan.","Cesano appointed to nominating & governance and R&D committees; Derek Miller becomes chair of nominating committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251238,"accession_number":"0001193125-24-002851","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zymeworks amends CEO employment to allow UK-based work, removes Vancouver relocation requirement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Kenneth Galbraith's principal place of employment changed to UK home, no longer required to relocate to Vancouver or Seattle.","Company will reimburse travel and lodging for one trip per year for Galbraith and immediate family to Vancouver/Seattle.","Company will continue to secure and pay rental costs for temporary housing in Vancouver, grossed up for tax withholding.","Amendment dated January 3, 2024; effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251237,"accession_number":"0001193125-24-001850","cik":1937653,"company_name":"Zymeworks Inc.","ticker":"ZYME","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Zymeworks reports $455M cash, runway into 2H 2027; zanidatamab Phase 3 data expected 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash resources of $455M as of Dec 31, 2023; expected funding into second half of 2027.","Top-line data from Phase 3 HERIZON-GEA-01 trial for zanidatamab in first-line HER2+ GEA expected in 2024.","Regulatory reviews ongoing in 2024 for zanidatamab in second-line BTC in US and China with Jazz and BeiGene.","IND filings planned for ZW171 and ZW191 in 2024; ZW220 and ZW251 in 2025; R&D Day in Q4 2024.","Completed $50M private placement with EcoR1 Capital, contributing to extended cash runway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1781760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}